Anticancer Antibody Receives First Funds for Trial in Leukemia Patients

An anti-leukemia compound identified at NCI at Frederick is one step closer to entering clinical trials in humans thanks to a $4.2-million grant from the Cancer Prevention and Research Institute of Texas (CPRIT). CPRIT recently gave the funds to Allterum Therapeutics, Inc., a Texas-based biotechnology startup company created to manufacture the compound, Allterum, and advance it to human trials. The grant represents the first step in the multi-million-dollar process to bring Allterum to the clinic.


“Something Just Clicked”: Partnership Pushes New Class of Cancer Drug Toward Human Trials

Serguei Kozlov, Ph.D., doesn’t recall if it was he who first contacted clinician Udo Rudloff, M.D., Ph.D., or Rudloff who contacted him. He just knows that their resulting two-year collaboration, which recently moved a first-in-class drug for metastatic cancer toward clinical trials, is one of the best he’s ever had.


NICBR Winter Symposium Focuses on Novel Therapeutics Research

Attendees packed the Building 549 Conference Center for the National Interagency Confederation for Biological Research (NICBR) Winter Symposium, the latest in a series that aims to foster collaboration between its eight member agencies. Each symposium focuses on a specific theme, with the most recent event organized around novel therapeutics.



Subscribe to Science